Drug repositioning

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Drug repositioning (often used interchangeably with drug repurposing) is re-investigating existing drugs that failed approval for new therapeutic indications. [1] [2][3]

Drug repurposing on the other hand is the application of already approved drugs and compounds to treat a different disease.

Using drug repositioning, pharmaceutical companies have achieved a number of successes; for example, Pfizer's Viagra for erectile dysfunction and Celgene's thalidomide for leprosy and multiple myeloma.[3][1] For companies dedicated to drug repositioning as a discovery strategy the approaches include in silico biology[4] and in vivo [5] /in vitro[6] experimentation to assess a compound and develop and confirm hypotheses concerning its usage for new indications.


From reference 1, published 2014: "Drug repurposing is the use of an approved drug or a drug under development for a different indication than that for which it was originally developed. Drug repositioning has recently been used to describe the novel use of a drug that was previously discontinued for development. (For the purposes of this workshop summary) drug repurposing and repositioning are used interchangeably."

See also[edit]

References[edit]

  1. ^ a b Institute of Medicine (2014). Drug Repurposing and Repositioning: Workshop Summary. National Academies Press. ISBN 978-0-309-30204-3.
  2. ^ Sleigh SH, Barton CL (23 August 2012). "Repurposing Strategies for Therapeutics". Pharmaceutical Medicine. 24 (3): 151–159. doi:10.1007/BF03256811.
  3. ^ a b Ashburn TT, Thor KB (August 2004). "Drug repositioning: identifying and developing new uses for existing drugs". Nature Reviews. Drug Discovery. 3 (8): 673–83. doi:10.1038/nrd1468. PMID 15286734.
  4. ^ "Biovista company website".
  5. ^ "Melior Discovery company website".
  6. ^ ""Recursion Pharmaceuticals company website".

Further reading[edit]